|
業務類別
|
Biotechnology |
|
業務概覽
|
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension. |
| 公司地址
| 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130 |
| 電話號碼
| +1 858 410-0266 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.skyebioscience.com |
| 員工數量
| 12 |
| Mr. John P. Sharp |
Chief Financial Officer and Principal Accounting Officer |
-- |
03/04/2026 |
| Mr. Chris Twitty, PhD |
Chief Scientific Officer |
-- |
16/04/2026 |
| Mr. Punit Dhillon |
Director, Principal Accounting Officer, President and Chief Executive Officer |
美元 610.00K |
20/02/2026 |
| Mr. Tuan Tu Diep |
Chief Operating Officer |
美元 440.00K |
16/04/2026 |
|
|
| Dr. Karen L. Smith, L.L.M.,M.B.A.,M.D.,PhD |
Independent Director |
16/04/2026 |
| Dr. Annalisa Mary Jenkins, F.R.C.P.,M.B.B.S. |
Independent Director |
16/04/2026 |
| Mr. Punit Dhillon |
Director, Principal Accounting Officer, President and Chief Executive Officer |
20/02/2026 |
| Mr. Paul Grayson |
Chairman of the Board |
16/04/2026 |
| Dr. Deborah Charych |
Independent Director |
16/04/2026 |
| Dr. Andrew J. Schwab, PhD |
Director |
16/04/2026 |
|
|
|
|
